EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Growth Hormone Treatment in Children From an Extended Family With ACAN ‐Related Short Stature

Einat Shalev-Goldman, Ayman Asaly, Hadas Ityel, Ben Pode-Shakked, Dalit Modan-Moses, Yael Levy-Shraga iD

Clinical Genetics · 2026

DOI: 10.1111/cge.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Einat Shalev-Goldman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Aggrecans, Human Growth Hormone, Growth Disorders, Dwarfism. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterozygous variants in the ACAN gene are a recognized cause of short stature. We aimed to evaluate the response to growth hormone (GH) treatment in members of an extended family carrying an ACAN variant. Clinical and laboratory data of five related children were retrospectively collected. GH therapy was initiated at a mean age of 3.2 ± 2.1 years and treated for 6.4 ± 5.0 years. The height standard deviation scores (SDS) increased from −3.3 ± 1.0 to −2.0 ± 1.1 ( p = 0.001), with a mean gain of 1.3 ± 0.3 SDS. The most notable increase in growth velocity SDS occurred during the first year of treatment (−0.5 ± 0.6 to 2.1 ± 1.2; p = 0.04). No adverse effects were observed, and bone age did not advance significantly. Three children entered puberty between the ages of 10 and 11.6 years and received adjunctive gonadotropin releasing hormone analog therapy. Genetic testing identified a heterozygous nonsense variant in the ACAN (c.2023C>T; p.Arg675*). Our findings suggest that GH therapy can improve growth velocity in children with ACAN ‐related short stature, though the degree of response varies even within the same family. The long‐term impact on final adult height remains to be elucidated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AggrecansHuman Growth HormoneGrowth DisordersDwarfismGrowth HormoneHumansChildMaleFemaleBody HeightChild, PreschoolPedigreeRetrospective StudiesAdolescentHeterozygoteExtended Family

Stichwörter der Autor:innen

ACANgrowth hormoneidiopathic short staturetreatment

Substanzen

ACAN protein, humanAggrecansHuman Growth HormoneGrowth Hormone

Autor:innen und Institutionen

  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Endocrinology and Diabetes Unit, the Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
  • The Institute for Rare Diseases, the Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel.

ORCID-Profile: Yael Levy-Shraga

Zitieren

APA

Shalev-Goldman, E., Asaly, A., Ityel, H., Pode-Shakked, B., Modan-Moses, D., & Levy-Shraga, Y. (2026). Impact of Growth Hormone Treatment in Children From an Extended Family With ACAN ‐Related Short Stature. Clinical Genetics. https://doi.org/10.1111/cge.70050

Vancouver

Shalev-Goldman E, Asaly A, Ityel H, Pode-Shakked B, Modan-Moses D, Levy-Shraga Y. Impact of Growth Hormone Treatment in Children From an Extended Family With ACAN ‐Related Short Stature. Clinical Genetics. 2026. doi:10.1111/cge.70050

BibTeX
@article{ShalevGoldman2026,
  author = {Shalev-Goldman, Einat and Asaly, Ayman and Ityel, Hadas and Pode-Shakked, Ben and Modan-Moses, Dalit and Levy-Shraga, Yael},
  title = {Impact of Growth Hormone Treatment in Children From an Extended Family With ACAN ‐Related Short Stature},
  journal = {Clinical Genetics},
  year = {2026},
  doi = {10.1111/cge.70050}
}
Kostenlos starten →